Alexandros Briasoulis1, Omar Al Dhaybi2, George L Bakris3. 1. Department of Cardiovascular Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, USA. 2. ASH Comprehensive Hypertension Center, The University of Chicago Medicine, 5841 S. Maryland Ave, Chicago, IL, 60637, USA. 3. ASH Comprehensive Hypertension Center, The University of Chicago Medicine, 5841 S. Maryland Ave, Chicago, IL, 60637, USA. gbakris@gmail.com.
Abstract
PURPOSE OF REVIEW: We sought to review currently available data on the safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 2 diabetes mellitus patients with hypertension. RECENT FINDINGS: Inhibition of SGLT2 in the renal proximal tubule results in increased urinary glucose excretion and modest improvements of hemoglobin A1C. Treatment with any of the three currently FDA-approved SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin) results in sustained systolic and diastolic blood pressure reduction, in part via minimal natriuresis and possible reductions in sympathetic tone. Recent randomized clinical trials in high cardiovascular risk patients with type 2 diabetes suggest that the unique effects of SGLT2 inhibitors on blood pressure and body weight may translate into reduced cardiovascular events and slowed kidney disease progression. However, concerns about volume depletion and acute kidney injury have been raised. SGLT2 inhibitors are viable second-line glucose-lowering agents for people with type 2 diabetes with high cardiovascular risk.
PURPOSE OF REVIEW: We sought to review currently available data on the safety and efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors in type 2 diabetes mellituspatients with hypertension. RECENT FINDINGS: Inhibition of SGLT2 in the renal proximal tubule results in increased urinary glucose excretion and modest improvements of hemoglobin A1C. Treatment with any of the three currently FDA-approved SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin) results in sustained systolic and diastolic blood pressure reduction, in part via minimal natriuresis and possible reductions in sympathetic tone. Recent randomized clinical trials in high cardiovascular risk patients with type 2 diabetes suggest that the unique effects of SGLT2 inhibitors on blood pressure and body weight may translate into reduced cardiovascular events and slowed kidney disease progression. However, concerns about volume depletion and acute kidney injury have been raised. SGLT2 inhibitors are viable second-line glucose-lowering agents for people with type 2 diabetes with high cardiovascular risk.
Entities:
Keywords:
Cardiovascular events; Diabetes; Glucose; Hypertension; SGLT2; Transporters; Weight loss
Authors: Despoina Vasilakou; Thomas Karagiannis; Eleni Athanasiadou; Maria Mainou; Aris Liakos; Eleni Bekiari; Maria Sarigianni; David R Matthews; Apostolos Tsapas Journal: Ann Intern Med Date: 2013-08-20 Impact factor: 25.391
Authors: Tim Heise; Jens Jordan; Christoph Wanner; Martina Heer; Sreeraj Macha; Michaela Mattheus; Søren S Lund; Hans J Woerle; Uli C Broedl Journal: Clin Ther Date: 2016-09-28 Impact factor: 3.393
Authors: Hala Yamout; Vlado Perkovic; Melanie Davies; Vincent Woo; Dick de Zeeuw; Cristiana Mayer; Ujjwala Vijapurkar; Irina Kline; Keith Usiskin; Gary Meininger; George Bakris Journal: Am J Nephrol Date: 2014-07-17 Impact factor: 3.754
Authors: Mikhail Kosiborod; Matthew A Cavender; Alex Z Fu; John P Wilding; Kamlesh Khunti; Reinhard W Holl; Anna Norhammar; Kåre I Birkeland; Marit Eika Jørgensen; Marcus Thuresson; Niki Arya; Johan Bodegård; Niklas Hammar; Peter Fenici Journal: Circulation Date: 2017-05-18 Impact factor: 29.690
Authors: Ryousuke Satou; Michael W Cypress; T Cooper Woods; Akemi Katsurada; Courtney M Dugas; Vivian A Fonseca; L Gabriel Navar Journal: Am J Physiol Renal Physiol Date: 2019-11-04
Authors: Jenny Hui Ling Chieng; Tze Kai Sia; Yao Hao Teo; Joseph Zi An Wong; Tricia Jing Ying Ng; Yao Neng Teo; Nicholas L X Syn; Robin Cherian; Yoke-Ching Lim; Ping Chai; Weiqin Lin; Raymond C C Wong; Ching-Hui Sia Journal: Med Princ Pract Date: 2022-04-04 Impact factor: 2.132
Authors: Daniel Stehle; Min Ze Xu; Tibor Schomber; Michael G Hahn; Frank Schweda; Susanne Feil; Jan R Kraehling; Frank Eitner; Andreas Patzak; Peter Sandner; Robert Feil; Agnès Bénardeau Journal: Br J Pharmacol Date: 2021-07-03 Impact factor: 9.473